fbpx

Vivos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

The Company conducted a conference call March 25, 2021 at 5:00 p.m. (Eastern Time) to review the results as well as provide an overview of the Company’s recent milestones and growth strategy.

An Important Breakthrough in the

Treatment for Mild-to-Moderate

Obstructive Sleep Apnea

Vivos Therapeutics Inc., is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA.

Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA.

Email Alerts

Stay informed and receive company updates straight to your inbox

Sign Up Now

VivoScore

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA), today announced the launch of VivoScore™, powered by SleepImage®.

Read Now

Latest Stock Information

Investor Presentation

Download the Vivos Investor Presentation.

Download Now
Fourth Quarter and Full Year 2020 Financial Results
Read Now

Vivos Therapeutics News + Events!

News + Events

Corporate Leadership

Our leadership team is devoted to a singular mission - to rid the world of sleep apnea.

15,000

Over 15,000 Patients Treated

1,200

Doctors Integrated + Trained

1

Over 1B Potential Patients

Investor Relations Contacts

Home Office

Vivos Therapeutics, Inc.
(866) 908-4867
9135 S Ridgeline Blvd
Suite 100
Highlands Ranch, CO
80129

Capital Markets

Edward Loew
Investment Relations Officer
(602) 903-0095
9137 S Ridgeline Blvd
Suite 135
Highlands Ranch, CO
80129

Investor Relations

Phil Carlson / Scott Eckstein
KCSA Strategic Communications
212-896-1210
[email protected]

Transfer Agent

Vstock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
Phone: 212.828.8436
Fax: 646-536-3179
Email: [email protected]